Clinical Trial Update: APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies [EARLY_Phase 1]

View source ↗

Summary

APG-2575 is being studied in a Phase 1 trial to evaluate its safety, tolerability, and PK/PD in patients with hematologic malignancies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• APG-2575

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: Hematologic Malignancies | EARLY_Phase 1 | Status: RECRUITING